Conformationally-Constrained Paclitaxels as Anticancer Agents


This technology is a new class of paclitaxel analogs.  The general structure includes a bridging bond that constrains the 3-D structure of the compound.  The resulting conformation of the paclitaxel analog promotes binding to and polymerization of tubulin.

US Patent 7,312,240  

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Conformationally Constrained Paclitaxels Analogs and Their Use as Anticancer and Anti-Alzheimers Agents US Utility *United States 11/035,037 7,312,240 1/14/2005 12/25/2007 12/4/2025 Issued
For Information, Contact:
Mike Miller
Senior Licensing Manager
Virginia Tech Intellectual Properties, Inc.
(540) 443-9228
David Kingston
Thota Ganesh
James Snyder
Ami Lakdawala
Susan Bane
Pharmaceuticals & Biotechnology
© 2020. All Rights Reserved. Powered by Inteum